Promoted Content
Promoted Content

Find Oncology Drugs in Phase III Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Idecabtagene Vicleucel

            Therapeutic Area: Oncology Product Name: Ide-cel

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2021

            Details:

            The data from the study demonstrates deep and durable responses with ide-cel treatment in triple-class exposed RRMM patients. In the KarMMa study, ide-cel demonstrated a safety profile consistent with known toxicities of CAR T cell therapies, regardless of dose level.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tebentafusp

            Therapeutic Area: Oncology Product Name: IMCgp100

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 19, 2021

            Details:

            FDA has granted Breakthrough Therapy Designation for tebentafusp based on the survival benefit from our Phase 3 clinical trial announced in November 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Durvalumab,Tremelimumab

            Therapeutic Area: Oncology Product Name: Imfinzi

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 05, 2021

            Details:

            KESTREL Phase III trial of Imfinzi (durvalumab) failed to meet the primary endpoint in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumours expressed high levels of PD-L1.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tebentafusp

            Therapeutic Area: Oncology Product Name: IMCgp100

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Goldman Sachs

            Deal Size: $200.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 01, 2021

            Details:

            Immunocore's pipeline contains its most advanced candidate, tebentafusp, which the company states has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase 3 trial in previously untreated metastatic uveal melanoma.